Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
Level V
Where this comes from
- Record sourced from PubMed, PMID 21670086.
- Also identified by DOI 10.1158/1078-0432.CCR-11-1218 and PMC identifier 3221729.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Benzoquinones
- Breast Neoplasms
- Genes, erbB-2
- HSP90 Heat-Shock Proteins
- Lactams, Macrocyclic